Infection News

SCOTTSDALE, Ariz. — Physical medicine and rehabilitation play an important role in recovering from fatigue symptoms in immune-mediated diseases, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

SCOTTSDALE, Ariz. — Long COVID, fibromyalgia and chronic fatigue syndrome demonstrate overlapping characteristics that warrant further investigation, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

SCOTTSDALE, Ariz. —The COVID-19 pandemic could enable better understanding of the relationship between infection and autoimmunity, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Last autumn, the availability of the 2023-2024 updated COVID-19 vaccines, which more closely targeted the then-dominant XBB omicron subvariant lineage, promised to restore protections that had waned over time.

Children with obesity demonstrate a greater likelihood of shock, ICU admission and worse laboratory scores in multisystem inflammatory syndrome, but not Kawasaki disease, according to data published in JAMA Network Open.

What should rheumatologists know about what we've learned about COVID-19 and long COVID in 2023? Hosted by Dr. Leonard Calabrese.

In patients with immune-mediated inflammatory diseases, a 2-week pause of methotrexate after receiving a COVID-19 vaccine booster yielded a sustained, significantly increased antibody response, without serious flares, according to a study.

SAN DIEGO — COVID-19 vaccine boosters led to a significantly increased antibody response in patients using abatacept or TNF inhibitors regardless of whether they held medication, according to data presented at ACR Convergence 2023.

Among patients with rheumatoid arthritis, the chosen course of therapy does not have an impact on the risk for developing a serious infection, according to data published in Rheumatology.

SAN DIEGO — A longer interval between the second and third SARS-CoV-2 vaccine doses results in greater antibody response in patients with inflammatory rheumatic diseases, according to data presented at ACR Convergence 2023.